European phase 3 trial of Aimmune Therapeutics’ AR101 meets primary endpoint
Aimmune Therapeutics announced that its phase 3 European clinical trial of AR101 for treatment of peanut allergy, known as ARTEMIS (AR101 Trial in Europe Measuring oral Immunotherapy Success), met its primary efficacy endpoint. March 25, 2019